Quotient Sciences intends to construct clinical and commercial pharmaceutical manufacturing space within a newly constructed spec building in the Garnet Valley Plaza in Garnet Valley, PA. The new production space will eventually replace existing the GMP manufacturing being conducted in an aged facility located several townships from the new site.
The facility to be vacated suffers from an ad hoc expansion that has taken place over three decades. Production flows are inefficient, there is a lack of flexibility and range in production capacity, and risks of cross-contamination have been affecting QS’ GMP compliance and marketing efforts.
The new facility is adjacent to QS’ recently built clinical manufacturing facility in order to consolidate and unify operations in the Philadelphia area. The design team has helped to identify and take advantage of the many synergies possible in the new program due to this proximity, such as the opportunity to share conference space, optimize the use of open shared office space in the new Covid-19 normal, and eliminate redundancies in site amenities and shipping and receiving.
FCA has assisted QS in the evaluation of conditions of the proposed tenant space and has developed a full needs assessment and test fits through a series of programming and planning workshops. The design team is currently providing full architectural and engineering services, including pharmaceutical equipment planning and interior design. A complete set of design documents and specs based on informed decisions will soon be completed to help QS achieve its objectives.
